m6A Writer METTL3-Mediated lncRNA LINC01125 Prevents the Malignancy of Papillary Thyroid Cancer
-
Published:2023
Issue:3
Volume:43
Page:43-53
-
ISSN:1040-8401
-
Container-title:Critical Reviews in Immunology
-
language:en
-
Short-container-title:Crit Rev Immunol
Author:
He Tianyou,Xia Hailiang,Chen Baojie,Duan Ziqi,Huang Chaogang
Abstract
<b>Background:</b> Long non-coding RNA (lncRNA) LINC01125 is an anti-tumor factor in a variety of tumors, and regulates cancer cell function. However, its function and mechanism of N6-methyladenosine (m6A) modification in papillary thyroid cancer (PTC) tumorigenesis remain unclear.
<b>Aims:</b> This study aimed to reveal the function and m6A modification of LINC01125 in PTC tumorigenesis.
<b>Methods:</b> The LINC01125 and methyltransferase-like 3 (METTL3) levels in PTC cells and tissues was assessed by qRT-PCR. The binding relationship among LINC01125 and METTL3 was determined by MeRIP, Pearson, bioinformatics, and RNA stabilization analysis. Transwell assays were performed to confirm the changes of PTC cell migration and invasion. Cell proliferation was revealed by CCK-8 as well as colony formation assays.
<b>Results:</b> Low expression of LINC01125 and METTL3 was identified in PTC. LINC01125 was a downstream target of METTL3-mediated m6A modification and was stably upregulated via METTL3. Cell invasion, migration, viability, and colony formation levels were decreased when LINC01125 or METTL3 was upregulated. Inhibition of LINC01125 had the opposite impact, promoting cell proliferation and metastasis, and reversing METTL3 overexpression-resulted cell malignancy suppression.
<b>Conclusions:</b> Overall, this study proved that the m6A modification of LINC01125 was mediated by METTL3 and LINC01125 inhibited cell invasion, migration and proliferation, thereby suppressing the development of PTC. This points to the LINC01125-m6A-METTL3 axis as a possible prospective target for future treatment of PTC.
Subject
Immunology,Immunology and Allergy
Reference26 articles.
1. Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol. 2020;16(1):17-29. 2. Yang H, Liang Q, Zhang J, Liu J, Wei H, Chen H, Wei W, Chen D, Zhao Y. Establishment of papillary thyroid cancer organoid lines from clinical specimens. Front Endocrinol. 2023;14:1140888. 3. Coca-Pelaz A, Shah JP, Hernandez-Prera JC, Ghossein RA, Rodrigo JP, Hartl DM, Olsen KD, Shaha AR, Zafereo M, Suarez C, Nixon IJ, Randolph GW, Makitie AA, Kowalski LP, Vander Poorten V, Sanabria A, Guntinas-Lichius O, Simo R, Zbaren P, Angelos P, Khafif A, Rinaldo A, Ferlito A. Papillary thyroid cancer-aggressive variants and impact on management: A narrative review. Adv Ther. 2020;37(7):3112-28. 4. Zhang J, Fu C, Cui K, Ma X. Papillary thyroid carcinoma with tracheal invasion: A case report. Medicine. 2019;98(38):e17033. 5. Ulisse S, Baldini E, Lauro A, Pironi D, Tripodi D, Lori E, Ferent IC, Amabile MI, Catania A, Di Matteo FM, Forte F, Santoro A, Palumbo P, D'Andrea V, Sorrenti S. Papillary thyroid cancer prognosis: An evolving field. Cancers. 2021;13(21).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|